Published in Pharma Law Weekly, December 29th, 2009
"The aim of this study was to assess the predictors (logistic regression) of severe fibrosis (METAVIR score F3-F4), and sustained virological response (SVR) to peginterferon and ribavirin in 226 consecutive HCV-4 patients (Egyptians 40%, Europeans 35% and Africans 24%). Insulin resistance was assessed using the homeostasis model (HOMA-IR). Serum HCVRNA level (bDNA) and subtypes of HCV (LiPA) were determined for all patients. Insulin resistance...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2009-12-29)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.